Investigational Allo-HSCT for Advanced Hematologic Malignanc

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

Related Keywords

, Optimizing Outcomes , Allogeneic Transplants , Advanced Hematologic , Hematologic Malignancies , Hematologic Cancers , Allo Hsct , Allogeneic Transplant , Allo Transplant , Relapsed , Refractory , High Risk , Advanced Hematologic Malignancies , Investigational Allo Hsct ,